MORGAN STANLEY PLC/PUT/NOVO NORDISK ADR B/100/0.1/17.01.25 Share Price

Warrant

DE000ME1Z139

Market Closed - Börse Stuttgart 12:47:57 06/07/2024 am IST
0.145 EUR +9.02% Intraday chart for MORGAN STANLEY PLC/PUT/NOVO NORDISK ADR B/100/0.1/17.01.25
Current month+20.83%
1 month+2.11%
Date Price Change
05/24/05 0.145 +9.02%
04/24/04 0.133 -16.35%
03/24/03 0.159 +25.20%
02/24/02 0.127 +12.39%
01/24/01 0.113 -5.83%

Delayed Quote Börse Stuttgart

Last update July 06, 2024 at 12:47 am IST

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME1Z13
ISINDE000ME1Z139
Date issued 12/10/2023
Strike 100 $
Maturity 17/01/2025 (196 Days)
Parity 10 : 1
Emission price 1.44
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.53
Lowest since issue 0.101
Delta-0.08x
Omega 6.748
Premium30.88x
Gearing89.35x
Moneyness 0.7024
Difference Strike -42.37 $
Difference Strike %-42.37%
Spread 0.006
Spread %4.00%
Theoretical value 0.1470
Implied Volatility 39.74 %
Total Loss Probability 87.55 %
Intrinsic value 0.000000
Present value 0.1470
Break even 98.41 €
Theta-0.01x
Vega0.01x
Rho-0x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974 DKK
Average target price
952.2 DKK
Spread / Average Target
-2.24%
Consensus